Leukemia Research
Volume 33, Issue 11 , Pages 1485-1489, November 2009

Phase II study of interleukin-12 for treatment of plateau phase multiple myeloma (E1A96): A trial of the Eastern Cooperative Oncology Group☆

  • Martha Q. Lacy

      Affiliations

    • Mayo Clinic, Rochester, MN, United States
    • Corresponding Author InformationCorresponding author at: Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, United States. Tel.: +1 507 284 8430; fax: +1 507 266 4972.
    • ,
  • Susanna Jacobus

      Affiliations

    • Dana Farber Cancer Institute, Boston, MA, United States
    • ,
  • Emily A. Blood

      Affiliations

    • Dana Farber Cancer Institute, Boston, MA, United States
    • ,
  • Neil E. Kay

      Affiliations

    • Mayo Clinic, Rochester, MN, United States
    • ,
  • S. Vincent Rajkumar

      Affiliations

    • Mayo Clinic, Rochester, MN, United States
    • ,
  • Philip R. Greipp

      Affiliations

    • Mayo Clinic, Rochester, MN, United States

Received 1 December 2008; received in revised form 1 December 2008; accepted 18 January 2009. published online 07 March 2011.

Abstract 

The Eastern Cooperative Oncology Group (ECOG) conducted a phase II trial of interleukin-12 (IL-12) for plateau phase multiple myeloma. Patients were initially treated with IL-12 250ng/kg I.V. daily for 5 days every 3 weeks. The trial was modified due to toxicity after the first 16 patients. IL-12 was given 300ng/kg subcutaneously twice weekly for 24 weeks. Of 48 eligible patients, there were 4 objective responses (8.3%), all CR. The median survival and progression-free survival were 42.8 and 11.4 months. Unacceptable grade 3 or 4 non-hematologic toxicity (31% with IL-12 subcutaneously and 63% with IL-12 intravenously) was observed.

Keywords: Multiple myeloma, Interleukin-12, Immunomodulatory therapy

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

☆ This study was conducted by the Eastern Cooperative Oncology Group (Robert L. Comis, M.D.) and supported in part by Public Health Service Grants CA23318, CA66636, CA21115, CA13650 and from the National Cancer Institute, National Institutes of Health and the Department of Health and Human Services. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute.

PII: S0145-2126(09)00027-7

doi:10.1016/j.leukres.2009.01.020

Leukemia Research
Volume 33, Issue 11 , Pages 1485-1489, November 2009

Article Tools

* Image Usage & Resolution